CN102512655A - L-carnitine composition, L-carnitine preparation and preparation method and application thereof - Google Patents
L-carnitine composition, L-carnitine preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN102512655A CN102512655A CN2011103915121A CN201110391512A CN102512655A CN 102512655 A CN102512655 A CN 102512655A CN 2011103915121 A CN2011103915121 A CN 2011103915121A CN 201110391512 A CN201110391512 A CN 201110391512A CN 102512655 A CN102512655 A CN 102512655A
- Authority
- CN
- China
- Prior art keywords
- carnitine
- preparation
- vitamin
- compositions
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 22
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 21
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 21
- 244000068988 Glycine max Species 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 46
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 27
- 229960003624 creatine Drugs 0.000 claims description 23
- 239000006046 creatine Substances 0.000 claims description 23
- 229960003080 taurine Drugs 0.000 claims description 22
- 235000012661 lycopene Nutrition 0.000 claims description 18
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 17
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 17
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 17
- 229960004999 lycopene Drugs 0.000 claims description 17
- 239000001751 lycopene Substances 0.000 claims description 17
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 17
- 238000005303 weighing Methods 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 230000001965 increasing effect Effects 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 235000019156 vitamin B Nutrition 0.000 claims description 3
- 239000011720 vitamin B Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 25
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 230000000386 athletic effect Effects 0.000 abstract 1
- 238000002485 combustion reaction Methods 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 24
- 230000033001 locomotion Effects 0.000 description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- 206010016256 fatigue Diseases 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 239000004310 lactic acid Substances 0.000 description 12
- 235000014655 lactic acid Nutrition 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000008187 granular material Substances 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 229960000310 isoleucine Drugs 0.000 description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000004474 valine Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960002743 glutamine Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- -1 hydroxyl isomaltulose Chemical compound 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- BQMPVGMHZKZPBH-BYZBDTJCSA-N (3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O BQMPVGMHZKZPBH-BYZBDTJCSA-N 0.000 description 1
- NRTLIYOWLVMQBO-UHFFFAOYSA-N 5-chloro-1,3-dimethyl-N-(1,1,3-trimethyl-1,3-dihydro-2-benzofuran-4-yl)pyrazole-4-carboxamide Chemical compound C=12C(C)OC(C)(C)C2=CC=CC=1NC(=O)C=1C(C)=NN(C)C=1Cl NRTLIYOWLVMQBO-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229930187479 gypenoside Natural products 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 150000002664 lycopenes Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009183 running Effects 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an L-carnitine composition, an L-carnitine preparation and a preparation method and application thereof. The composition can comprise L-carnitine or a salt thereof acceptable pharmaceutically, kreatine, branched-chain amino acid, glutamine and soybean peptide. The composition used for improving tolerance can increase the combustion of fat in a human body, effectively oxidize the fat in the human body and decompose the fat into energy, implements nutrition required by the human body, and improves the athletic ability.
Description
Technical field
The present invention relates to a kind of health food that contains L-carnitine, be specifically related to a kind of L-carnitine compositions and preparation.
Background technology
Exercise fatigue refers to that the physiological process of physical function can not continue can not keep predetermined exercise intensity at specified level and/or integral body.The generation of exercise fatigue is many-sided, as: metabolic waste is piled up, movable desired substance exhaustion etc.During high-intensity exercise, energy requirement is greater than the maximum aerobic metabolism power and the high-caliber anaerobic metabolism of needs of individuality.When maximum intensity moved to fatigue, phosphagen (CP) was by lot of consumption (reaching reserves 90%), and then concentration reduces in muscle; Can cause fatigue; The energize of the generation of ADP and ATP constantly consumes in the mitochondrion, as ADP again phosphorylation generate ATP speed and slow down, also can cause fatigue.H+ is the important reason of exercise fatigue, and when exercise fatigue, muscle pH can reduce to 6.33, and this is to cause tired principal element: 1) suppress the phosphofructokinase activity and reduction sugar decomposition speed; 2) competitive inhibition Ca
2+Reduce the cross-bridges activeness in conjunction with TnC; 3) suppress sarcoplasmic reticulum ATP-ase and reduce Ca
2+Heavily absorb and Ca subsequently
2+Discharge.
One Chinese patent application 200510086556.8 (title: a kind of beverage that promotes sportive recovery from fatigue; Open day: on April 19th, 2006) a kind of beverage that promotes sportive recovery from fatigue is provided; Its main component is L-glutaminate, taurine, creatine, vitamin, gypenoside and glucose, can also add trace element and lactalbumins such as ferrum, zinc.The effects of component aspect resisting fatigue such as glutamine, taurine, creatine, vitamin are promptly disclosed; But effect is relatively poor, and the inventor is through a large amount of discovering, an amount of increase some or change some compositions after; Can more efficientlyly slow down the generation of exercise fatigue, improve exercise tolerance.
Summary of the invention
The purpose of this invention is to provide a kind of L-carnitine compositions, it can quicken the burning of fat in the health, makes the body fat oxidation Decomposition be converted into energy effectively, replenishes the required nutrition of health, improves motor capacity.
Another object of the present invention is to provide a kind of L-carnitine preparation.
Another purpose of the present invention is to provide the method for preparing of said L-carnitine preparation.
A purpose more of the present invention has been to provide a kind of said L-carnitine compositions or preparation to improve the application in the endurance medicine in preparation.
The present invention provides a kind of L-carnitine compositions; By weight, comprise following raw material: L-carnitine or its pharmaceutically acceptable salt 10-300 part, glutamine 500-1500 part; Branched-chain amino acid 300-600 part, soybean peptide 100-300 part and creatine 100-300 part.
Described L-carnitine compositions by weight, preferably comprises following raw material: L-carnitine or its pharmaceutically acceptable salt 25-200 part, glutamine 800-1200 part, branched-chain amino acid 400-500 part, soybean peptide 150-250 part and creatine 150-250 part.
Described L-carnitine compositions by weight, more preferably comprises following raw material: 150 parts of L-carnitine or its pharmaceutically acceptable salts, 900 parts of glutamine, 450 parts of branched-chain amino acid, 180 parts of 200 parts of soybean peptide and creatines.
Described L-carnitine compositions, the raw material that also comprises has: taurine, vitamin substances and lycopene.
Wherein, by weight, said taurine 5-60 part, vitamin substances 5-15 part, lycopene 0.5-2.5 part.Preferred taurine 15-50 part, vitamin substances 8-12 part, lycopene 1-2 part.More preferably taurine is 35 parts, 10 parts of vitamin substances, 1.5 parts of lycopenes.
Wherein, said L-carnitine pharmaceutically acceptable salt is selected from one or more in L-carnitine-L-tartrate, Carnitine Fumarate or the L-carnitine hydrochloride.
Wherein, said vitamin substances is vitamin B1, vitamin B2, vitamin C, vitamin B6 or vitamin E.
Wherein, said branched-chain amino acid is leucine, isoleucine and valine.Its weight ratio is (2.0-2.5): 1: (1.0-1.5), and preferred 2: 1: 1.
A kind of L-carnitine preparation provided by the invention is made up of said L-carnitine compositions and pharmaceutically acceptable excipient.
Wherein, said pharmaceutically acceptable excipient is selected from one or more in diluent, binding agent, sweeting agent and the lubricant.
Wherein, said diluent is selected from one or more in lactose, mannitol, microcrystalline Cellulose, hydroxyl isomaltulose, Sorbitol, xylitol and the isomaltulose.
Wherein, said binding agent is selected from one or both in ethanol and the hydroxypropyl methylcellulose.
Wherein, said lubricant is selected from one or both in magnesium stearate and the soybean oil.
Wherein, said sweeting agent is selected from a kind of many several kinds in Mel, white sugar and the citric acid.
Wherein, the weight portion of said pharmaceutically acceptable excipient is 10-2000 part, is preferably 10-1000 part, more preferably 300 parts.Excipient also is called adjuvant.
Said L-carnitine preparation can be solid preparation or liquid preparation.
Wherein, said solid preparation can be tablet, capsule or powder.Capsule can be made hard capsule or soft capsule.Said liquid preparation can be a drink liquid.
The unit of weight portion of the present invention can be the known unit of weights of field of medicaments such as μ g, mg, g, kg.
The method for preparing of said L-carnitine preparation provided by the invention can adopt conventional method in the art to prepare, and also can comprise the steps: through following method preparation
1) take by weighing each raw material in the said L-carnitine compositions, crushing screening, subsequent use;
2) take by weighing said pharmaceutically acceptable excipient, this excipient and said each raw material of step 1) according to the equivalent method mix homogeneously that progressively increases, are become various regular dosage forms according to the conventional formulation prepared.
Compositions of the present invention and preparation have following beneficial effect:
L-carnitine (L-carnitine) is claimed L-carnitine, DL-carnitine chloride again, and chemical name is beta-hydroxy γ-trimethylamine butanoic acid, is a kind of white crystalline lens or white transparent fine powder.L-carnitine is the moisture absorption very easily, and stable good can place in the solution of pH 3-6 more than 1 year, ability more than 200 ℃ high temperature and have molten preferably aqueous and water absorption.L-carnitine has been applied to fields such as medicine, health care and food at present.
L-carnitine is that a kind of fat that promotes is converted into the amino acid of energy, and red meat is the main source of L-carnitine, to the human non-toxic side effect.Dissimilar diets has contained the L-carnitine of 5-100 milligram, but common people can only take in 50 milligrams every day from meals, and vegetarian is taken in still less.The major physiological function of L-carnitine is to promote that fat changes into energy.L-carnitine and salt thereof are a kind of special acids that extensively is present in body tissue; It is lipometabolic necessary cofactor; Can improve sports emotion and enhancing body vigor, increase muscular endurance and motor capacity, there is positive effect aspects such as alleviation and resisting fatigue.
Soybean peptide is to adopt modern biological enzymolysis technology, after the soybean protein molecule is separated through enzyme action, and the small molecular protein peptide that obtains.It had both had soy proteinaceous nutritive peculiarity, had peculiar good biological activity of small-molecular peptides and physiological function again.Supplement the nutrients rapidly, strengthen nutrition, allaying tiredness for the athlete increases muscle quantities, regains one's strength.Soybean peptide is fast in intestinal absorption, has antioxidant activity, can also promote the increase of sport people lean body mass, improves the sport people serum testosterone, reduces the tired grade of sport people, reduces sport people motion back SCK level, the protection cell membrane.
Creatine is the natural nutrient that is present in body, and 95% creatine all is present in the skeletal muscle.The resynthesis of the ATP that consumes during the competent creatine of intramuscular can guarantee to move reduces the generation of the partial lactic acid of muscle to greatest extent, thereby people's physical ability is moved the longer time under higher intensity.This just can help human body to gain in strength, increase the acting ability, increase muscle, and makes human body fatigue can not take place too early.Research shows that creatine can increase the ability of muscle fiber panning protein.Actin and myosin all are essential for the contraction of all muscle.When human body through the picked-up creatine, when having promoted that these contractile proteins synthesize, then increased the ability that muscle is engaged in physical exertion, in the shorter time, can accomplish more work.Therefore creatine is good nutriment for the athlete who improves explosive force, carries out strength building.
Glutamine is in blood and the cell, the highest free amino acid of skeletal muscle intensive amount particularly, and it has constituted 61% of skeletal muscle free amino acid pond.The research about glutamine and taurine recently shows, they can promote the decomposition of proteinic anabolism and minimizing muscular tissue when human body produces intensive metabolic stress (body that is caused like exacting practice and match stress).Glutamine is the carrier of nitrogen, and has the effect of important cell increase-volume, and research shows that only replenishing glutamine 2-6g every day just has tangible positive interaction to protein metabolism and cell increase-volume.These effects all can promote the synthetic growth with cell of myocyte's internal protein.Discover in addition, use the low dose of glutamine can also stimulating immune system, serve as the fuel of immunocyte, correct acidosis, keep the normal pH value of blood.Yet the strength building of big intensity can make glutamine reduce by 50%, and the motion back just can return to original level in several hours.People's immunity after motion is low than usual, and this is that the decline of body glutamine level causes.If there is the problem of hypoimmunity in the athlete, in case they the flu or wound infection, the time of its recovery than under the normal condition slowly many, this also will hinder the completion of exercise program.This shows that replenishing of glutamine is very important concerning them.
Branched-chain amino acid (leucine, isoleucine, valine) after training, recover and procedure of adaptation in bring into play pivotal role, branched-chain amino acid is the precursor substance that muscular energy produces, and also is simultaneously immune system and activate the fuel that recovers mechanism.Therefore its tired and anti-muscle protein of bioavailability, delay that helps to improve carbohydrate decomposes.
Lycopene (lycopene) is the main pigment of ripe Fructus Lycopersici esculenti, is a kind of oxygen-free carotenoid.In carotenoid, it has the strongest antioxidant activity.The effect that lycopene is removed free radical outclass other carotenoid and vitamin E, and the speed constant of its cancellation singlet oxygen is 100 times of vitamin E, is one of found powerful antioxidant of occurring in nature up to now.
Taurine is a kind of special aminoacid, is the requisite a kind of nutrient of human body, and the effect of balance health is arranged.Scientific research finds that taurine all has protective effect to eyes, lung, liver, gastrointestinal etc.In addition, taurine can combine the hypochlorous acid in the leukocyte and generate the avirulence material, reduces the destruction of hypochlorous acid to leukocyte self; Thereby raising body immunity; Simultaneously, taurine can be kept cardiac function, makes blood circulation normalization; Thereby the allaying tiredness product makes body produce power effectively., it has the effect that alleviates and prevent myocardial damage after the motion of exhausting property of power, the motor capacity that can improve body after replenishing, it mainly is to realize through the tired generation of opposing body periphery.
Vitamin B group can promote energy metabolism, alleviates the mental pressure of movement human.Vitamin C and vitamin E can be removed free radical, improve immunologic function, reduce the injury of radical pair body, the generation of delay fatigue.
In a word; L-carnitine compositions provided by the invention makes up L-carnitine or its pharmaceutically acceptable salt, creatine, branched-chain amino acid, glutamine, soybean peptide, can add taurine, vitamin substances and lycopene again; Further, undertaken composite by special ratios.Wherein, L-carnitine is the fatty acid oxidation carrier, can fat be transferred to mitochondrion, in mitochondrion, carries out oxidation Decomposition, for body provides energy; Other materials are that body provides nutrition, thereby can improve the endurance of motion, slow down the generation of exercise fatigue and promote tired recovery.Especially can promote body SOD to raise effectively, strengthen the ability of body free radical resisting.
The specific embodiment
Following examples are used to explain the present invention, but are not used for limiting scope of the present invention.
Embodiment 1: capsule
1, prescription (weight): L-carnitine-L-tartrate 25g, VITAMIN B15 g, lycopene 1g, creatine 100g, branched-chain amino acid 300g (leucine 150g, isoleucine 75g, valine 75g), glutamine 500g, taurine 5g, soybean peptide 100g, isomaltulose 100g, magnesium stearate 10g.
2, method for preparing:
1) take by weighing L-carnitine-L-tartrate, vitamin B1, lycopene, creatine, branched-chain amino acid, glutamine, taurine, soybean peptide according to prescription, cross 40 mesh sieves respectively, subsequent use;
2) take by weighing isomaltulose and magnesium stearate according to prescription, above-mentioned supplementary material by the equivalent method mix homogeneously that progressively increases, is poured into capsule and filled in the mould, fill capsule, polishing, packing.
Embodiment 2: powder
1, prescription (weight): Carnitine Fumarate 300g, vitamin C 15g, lycopene 2.5g, creatine 300g, branched-chain amino acid 600g (leucine 300g, isoleucine 120g, valine 180g), glutamine 1500g, taurine 60g, soybean peptide 300g, hydroxyl isomaltulose 2000g.
2, method for preparing:
1) take by weighing L-carnitine-L-tartrate, vitamin C, lycopene, creatine, branched-chain amino acid, glutamine, taurine, soybean peptide according to prescription, cross 40 mesh sieves respectively, subsequent use;
2) take by weighing hydroxyl isomaltulose according to prescription, with above-mentioned supplementary material by the equivalent method mix homogeneously that progressively increases, packing.
Embodiment 3: tablet
1, prescription (weight): L-carnitine 150g, vitamin B
610g, lycopene 1.5g, creatine 180g, branched-chain amino acid 450g (leucine 125g, isoleucine 90g, valine 135g), glutamine 900g, taurine 35, soybean peptide 200g, microcrystalline Cellulose 700g, lactose 1200g, magnesium stearate 40g.
2, method for preparing:
1) take by weighing L-carnitine-L-tartrate, vitamin B6, lycopene, creatine, branched-chain amino acid, glutamine, taurine, soybean peptide according to prescription, cross 40 mesh sieves respectively, subsequent use;
2) take by weighing microcrystalline Cellulose, lactose, magnesium stearate according to prescription, by the equivalent method mix homogeneously that progressively increases, use 50% ethanol above-mentioned supplementary material, the system soft material as binding agent; Above-mentioned soft material is processed granule through waving of 14 eye mesh screens in the granulator, granule is inserted in the multi-functional boiling drier, about 40 minutes of 50 ℃ of airpillow-dry; The control pellet moisture is 5%, and granulate adds magnesium stearate then in granule; Total mixed, tabletting, packing.
Embodiment 4: capsule
Method for preparing is with embodiment 1, and the prescription of different is this capsule is:
L-carnitine-L-tartrate 50g, vitamin B2 8g, lycopene 1.8, creatine 150g, branched-chain amino acid 495g (leucine 275g, isoleucine 110g, valine 110g), glutamine 1000g, taurine 40g, soybean peptide 150g, microcrystalline Cellulose 100g, magnesium stearate 5g.
Embodiment 5: oral liquid
1, prescription (weight): L-carnitine-L-tartrate 12kg, glutamine 50kg, branched-chain amino acid 40kg, soybean peptide 20kg, creatine 15kg, Mel 10kg, white sugar 8kg, citric acid 1kg.
2, method for preparing:
1) take by weighing supplementary material, cross 40 mesh sieves respectively, subsequent use;
2) with above former, adjuvant except that Mel according to the equivalent method mix homogeneously that progressively increases, be dissolved in then in the 100kg water, add Mel and stir, be sub-packed in the aseptic bottle every bottle of 20ml after the sterilization.
Embodiment 6: powder
Method for preparing is with embodiment 2, and the component of different is this powder is:
L-carnitine-L-tartrate 100g, vitamin E 12g, lycopene 1.2g, creatine 120g, branched-chain amino acid 450g (leucine 200g, isoleucine 100g, valine 150g), glutamine 700g, taurine 50g, soybean peptide 120g, microcrystalline Cellulose 100g, magnesium stearate 5g.
Embodiment 7: tablet
1, prescription (weight): L-carnitine 60g, vitamin B2 18g, lycopene 1.8g, creatine 100g, branched-chain amino acid 380 (leucine 190g, isoleucine 95g, valine 95g)) g, glutamine 1200g, taurine 45g, soybean peptide 250g; Microcrystalline Cellulose 500g, magnesium stearate 10g, lactose 200g.
2, method for preparing:
1) take by weighing supplementary material, cross 40 mesh sieves respectively, subsequent use;
2) take by weighing microcrystalline Cellulose, magnesium stearate and lactose according to prescription, by the equivalent method mix homogeneously that progressively increases, use 50% ethanol above-mentioned supplementary material, the system soft material as binding agent; Above-mentioned soft material is processed granule through waving of 14 eye mesh screens in the granulator, granule is inserted in the multi-functional boiling drier, about 40 minutes of 50 ℃ of airpillow-dry, the control pellet moisture is 5%; Granulate adds magnesium stearate then in granule, total mixing; Tabletting, packing promptly gets.
Experimental example: human experimentation
1 experimental subject and method
1 experimental subject and method
1.1 experimental subject
Is object of study with 91 man's long-distance runnings of certain sport university to athlete's (21.8 ± 0.75 years old mean age).
1.2 experiment is divided into groups
Divide into groups: 91 experimenters are divided into 7 groups at random, and blank control group (N=13) is taken placebo, 4/day; Experimental group 1-5 takes the prepared sample of embodiment 1-5 respectively, and contrast groups is taken the product that embodiment 6 makes in the patent 200510086556.8,2 bags/day, all takes continuously for 8 weeks.Whole experimental session, and other improve the food and the medicine of endurance to prohibit clothes.
1.3 experimental technique
Venous blood when requiring the experimenter before test, to come laboratory on an empty stomach to get peace and quiet; Carry out sports load (on the Monark energy meter, moving) before the motion, first limber up 1min (0 load) begins with 50W power then; Increasing load progressively; Reach 70%Hrmax (drawing) about 3 minutes, after this promptly no longer increase loading, continue 60 minutes to pedal by trial test mensuration.Centre of motion rate adopts the monitoring of Polar table.Control breadboard temperature and humidity.The experimenter tests after taking 8 all nutriments once more.
1.4 index and method
Test index: get ear blood 1 per half an hour in the motion, surveys lactic acid.Immediate postexercise, motion back were measured the recovery heart rate on the the 3rd, 9,15 minute, are got ear blood survey lactic acid.Second day early morning, extracting vein blood was measured serum superoxide dismutases (SOD) vigor.
Method of testing: blood lactic acid adopts YSI 1500SPORT LACTATE ANALYZER to measure, and method is the enzyme electrode method; Serum superoxide dismutases (SOD) vigor adopts xanthine oxidase to measure, and determining instrument is 721 type spectrophotometers.
1.5 result's statistics
Date processing adopts SPSS10.0 software, and all data are represented with means standard deviation, adopt the variance and the pairing T method of inspection.
2 experimental results
2.1 the comparison of blood lactic acid concn
Table 1: blood lactic acid concn (unit: mmoL/L)
| Divide into groups | Quiet | Immediate postexercise | Motion finishes back 3min | Motion finishes back 9min | Motion finishes back 15min |
| Blank control group | 1.60±0.46 | 3.22±0.42 | 3.23±0.53 | 2.21±0.52 | 1.61±0.43 |
| Contrast groups | 1.59±0.45 | 2.92±0.46 | 2.66±0.54 | 2.01±0.53 | 1.58±0.47 |
| Experimental group 1 | 1.58±0.43 | 2.74±0.43 | 1.59±0.58 ** | 1.41±0.50 ** | 1.46±0.53 |
| Experimental group 2 | 1.61±0.51 | 2.78±0.40 | 1.62±0.54 ** | 1.39±0.48 ** | 1.38±0.49 |
| Experimental group 3 | 1.57±0.32 | 2.65±0.46 | 1.53±0.59 ** | 1.35±0.45 ** | 1.32±0.58 |
| Experimental group 4 | 1.58±0.34 | 2.70±0.42 | 1.58±0.56 ** | 1.34±0.44 ** | 1.35±0.53 |
| Experimental group 5 | 1.59±0.23 | 2.80±0.41 | 1.68±0.49 ** | 1.51±0.49 ** | 1.45±0.48 |
*The expression experimental group is compared p＜0.01 with blank control group;
The expression contrast groups is compared p＜0.05 with blank control group.
The result finds out from table 1:
Immediate postexercise, the blood lactic acid concn of each experimental group slightly reduces, but does not produce significant difference;
Motion finishes back 3min, and the blood lactic acid concn of each experimental group is compared with blank control group, has utmost point significant difference (P＜0.01); Contrast groups is compared with blank control group, has significant difference (P＜0.05);
Motion finishes back 9min, the level when the blood lactic acid concn of each experimental group returns to peace and quiet;
Motion finishes back 15min, the level when contrast groups and blank control group just return to peace and quiet.
Lactic acid is the product that the metabolism of energy substance decomposition obtains in the body in the motor process, a large amount of acidic materials accumulation, cause muscle, joint acid expand and spirit tired.Take the experimental group sample, help to accelerate the removing speed of blood lactic acid in the body, help prolonging exercise tolerance, improve motor capacity.
2.2 motion finishes to recover in back 3 minutes the comparison of heart rate
The heart rate of immediate postexercise and motion back 3min test subject, the result sees table 2.
Table 2: the heart rate that the motion end recovered in back 3 minutes (inferior/minute)
| Divide into groups | At once heart rate (inferior/minute) after motion finishes | The heart rate that the motion end recovered in back 3 minutes (inferior/minute) |
| Blank control group | 140.12±8.48 | 129.23±5.68 |
| Contrast groups | 141.15±6.49 | 119.28±5.73 & |
| Experimental group 1 | 138.45±6.99 | 107.54±6.23 ** |
| Experimental group 2 | 139.15±6.67 | 108.13±6.53 ** |
| Experimental group 3 | 142.32±7.12 | 106.57±6.74 ** |
| Experimental group 4 | 140.68±8.53 | 108.66±6.83 ** |
| Experimental group 5 | 141.35±7.26 | 110.64±7.12 ** |
*The expression experimental group is compared with blank control group, p＜0.01, and & representes that contrast groups compares p＜0.05 with blank control group.
Can find out by table 2:
Motion finishes back 3 minutes, and the recovery of each experimental group heart rate is compared with blank control group, highly significant (P＜0.01);
Contrast groups is compared with blank control group, and heart rate recovers significantly (P＜0.05).
The heart rate resume speed is fast, shows that experimental group experimenter exercise tolerance is good, and motor capacity is strong.Therefore can find out that experimental group experimenter's resisting fatigue effect is better than blank control group and contrast groups.
2.3 oxidation resistance test result
Experiment back m seq is measured serum superoxide dismutases (SOD) vigor of blank control group, contrast groups and each experimental group respectively, and experimental result is seen table 3.
Table 3: the experiment back is to the influence of 4 groups of experimenter's oxidation resistances
Compare ※ p＜0.05 with blank control group.
Can know that by table 3 the SOD vigor in five groups of experimenter mornings next day is all high than morning on the previous day, all is significantly higher than the previous day (P＜0.05).And contrast groups is compared with blank control group, does not have significant difference.
Show that present patent application obtains compositions and can promote body SOD to raise effectively, has strengthened the ability of body free radical resisting.
Discuss: motion causes that the body free radical increases, and too much free radical can cause some important metabolic enzymes because of the cross-linked polymeric inactivation, causes a series of pathological change, causes the ability to work of human body to descend and the generation feeling of fatigue.Therefore, accelerate the removing speed of free radical, improve the anti-oxidative defense function, help to improve motor capacity, promote fatigue recovery, reduce the damage of peroxidation body.
3, conclusion
From whole experiment; Antifatigue compositions provided by the invention has the effect of Synergistic, and experimenter's blood lactic acid resume speed is accelerated, and it is also fast that heart rate recovers; This all is the key factor that helps prolonging exercise tolerance, helps the raising of motor capacity.Motion can cause that the body free radical increases, and too much free radical can cause some important metabolic enzymes because of the cross-linked polymeric inactivation, causes a series of pathological change, causes the ability to work of human body to descend and generation fatigue.Therefore, accelerate the removing speed of free radical, improve the anti-oxidative defense function, significant to improving motor capacity.The antioxidation result of this experiment shows, takes the preparation that said composition processes and can promote body SOD to raise effectively, can improve the ability of body free radical resisting effectively, to improving motor capacity and promoting that fatigue recovery also has certain effect.
Though, used general explanation, the specific embodiment and test in the preceding text, the present invention has been done detailed description, on basis of the present invention, can to some modifications of do or improvement, this will be apparent to those skilled in the art.Therefore, these modifications or the improvement on the basis of not departing from spirit of the present invention, made all belong to the scope that requirement of the present invention is protected.
Claims (10)
1. a L-carnitine compositions is characterized in that, by weight; Comprise following raw material: L-carnitine or its pharmaceutically acceptable salt 10-300 part; Glutamine 500-1500 part, branched-chain amino acid 300-600 part, soybean peptide 100-300 part and creatine 100-300 part.
2. L-carnitine compositions according to claim 1; It is characterized in that; By weight, comprise following raw material: L-carnitine or its pharmaceutically acceptable salt 25-200 part, glutamine 800-1200 part; Branched-chain amino acid 400-500 part, soybean peptide 150-250 part and creatine 150-250 part.
3. L-carnitine compositions according to claim 1 and 2 is characterized in that, by weight; Comprise following raw material: 150 parts of L-carnitine or its pharmaceutically acceptable salts; 900 parts of glutamine, 450 parts of branched-chain amino acid, 180 parts of 200 parts of soybean peptide and creatines.
4. according to any described L-carnitine compositions of claim 1-3, it is characterized in that the raw material that said L-carnitine compositions also comprises has: taurine, vitamin substances and lycopene.
5. according to any described L-carnitine compositions of claim 1-4, it is characterized in that described L-carnitine pharmaceutically acceptable salt is selected from one or more in L-carnitine-L-tartrate, Carnitine Fumarate or the L-carnitine hydrochloride.
6. L-carnitine compositions according to claim 4 is characterized in that, said vitamin substances is a vitamin B
1, vitamin B
2, vitamin C, vitamin B
6Or vitamin E.
7. a L-carnitine preparation is characterized in that, is made up of any described L-carnitine compositions of claim 1-6 and pharmaceutically acceptable excipient.
8. L-carnitine preparation according to claim 7 is characterized in that said preparation is selected from solid preparation or liquid preparation; Said solid preparation is selected from tablet, capsule or powder; Said liquid preparation is selected from drink liquid.
9. a method for preparing claim 7 or 8 described L-carnitine preparations is characterized in that, comprises the steps:
1) take by weighing each raw material in the said L-carnitine compositions, crushing screening, subsequent use;
2) take by weighing said pharmaceutically acceptable excipient, this excipient and said each raw material of step 1) are progressively increased behind the method mix homogeneously according to equivalent, prepare said L-carnitine preparation.
10. described L-carnitine compositions of claim 1-6 or claim 7 or 8 described L-carnitine preparations are used in preparation raising endurance medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103915121A CN102512655B (en) | 2011-11-30 | 2011-11-30 | L-carnitine composition, L-carnitine preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103915121A CN102512655B (en) | 2011-11-30 | 2011-11-30 | L-carnitine composition, L-carnitine preparation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102512655A true CN102512655A (en) | 2012-06-27 |
| CN102512655B CN102512655B (en) | 2013-10-30 |
Family
ID=46283907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103915121A Active CN102512655B (en) | 2011-11-30 | 2011-11-30 | L-carnitine composition, L-carnitine preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102512655B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110114A (en) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | Beta-alanine-containing composition for endurance increase, and preparation thereof |
| CN104509919A (en) * | 2013-09-30 | 2015-04-15 | 张自力 | Functional nutrient beverage |
| CN104585763A (en) * | 2015-01-28 | 2015-05-06 | 广西博科药业有限公司 | Liver-protecting and liver-nourishing functional food and preparation method thereof |
| CN106617086A (en) * | 2016-12-30 | 2017-05-10 | 贝克尔（天津）药业有限公司 | Nutritional food capable of enhancing exercise capacity and exercise tolerance |
| CN106620667A (en) * | 2016-12-15 | 2017-05-10 | 钦州市钦南区科学技术情报研究所 | L-carnitine compound having effects of losing weight and reducing grease and preparation method thereof |
| CN108283314A (en) * | 2017-11-30 | 2018-07-17 | 新疆阜丰生物科技有限公司 | One kind containing L-Glutamine and three branched-chain amino acid compound health products and preparation method thereof |
| CN110801018A (en) * | 2019-11-08 | 2020-02-18 | 广东医科大学 | Coenzyme Q10Vitamin C sports buccal tablet |
| CN111228468A (en) * | 2020-01-14 | 2020-06-05 | 浙江赛沛力运动科技有限公司 | Liquid preparation with effects of improving exercise endurance and helping exercise recovery |
| CN113056206A (en) * | 2019-06-25 | 2021-06-29 | 代谢科技有限公司 | Stability of vitamin D in beta-hydroxy-beta-methylbutyric acid (HMB) |
| CN116076740A (en) * | 2023-03-13 | 2023-05-09 | 湖南她练生物科技有限公司 | Levocarnitine composition for improving metabolic fat function of sports females and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1251496A (en) * | 1997-04-01 | 2000-04-26 | 希格马托保健科学股份公司 | Nutritional supplement for promoting skeletal muscles to adapt strenuous exercise and resisting over fatigue of humanbody |
| CN1759761A (en) * | 2005-09-30 | 2006-04-19 | 北京康比特威创体育新技术发展有限公司 | Beverage for promoting sportive recovery from fatigue |
| CN101390639A (en) * | 2007-09-20 | 2009-03-25 | 中国食品发酵工业研究院 | Anti-fatigue solid beverage containing soya peptide |
-
2011
- 2011-11-30 CN CN2011103915121A patent/CN102512655B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1251496A (en) * | 1997-04-01 | 2000-04-26 | 希格马托保健科学股份公司 | Nutritional supplement for promoting skeletal muscles to adapt strenuous exercise and resisting over fatigue of humanbody |
| CN1759761A (en) * | 2005-09-30 | 2006-04-19 | 北京康比特威创体育新技术发展有限公司 | Beverage for promoting sportive recovery from fatigue |
| CN101390639A (en) * | 2007-09-20 | 2009-03-25 | 中国食品发酵工业研究院 | Anti-fatigue solid beverage containing soya peptide |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110114A (en) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | Beta-alanine-containing composition for endurance increase, and preparation thereof |
| CN103110114B (en) * | 2011-11-16 | 2014-05-28 | 北京康比特体育科技股份有限公司 | Beta-alanine-containing composition for endurance increase, and preparation thereof |
| CN104509919A (en) * | 2013-09-30 | 2015-04-15 | 张自力 | Functional nutrient beverage |
| CN104585763A (en) * | 2015-01-28 | 2015-05-06 | 广西博科药业有限公司 | Liver-protecting and liver-nourishing functional food and preparation method thereof |
| CN106620667A (en) * | 2016-12-15 | 2017-05-10 | 钦州市钦南区科学技术情报研究所 | L-carnitine compound having effects of losing weight and reducing grease and preparation method thereof |
| CN106617086A (en) * | 2016-12-30 | 2017-05-10 | 贝克尔（天津）药业有限公司 | Nutritional food capable of enhancing exercise capacity and exercise tolerance |
| CN108283314A (en) * | 2017-11-30 | 2018-07-17 | 新疆阜丰生物科技有限公司 | One kind containing L-Glutamine and three branched-chain amino acid compound health products and preparation method thereof |
| CN113056206A (en) * | 2019-06-25 | 2021-06-29 | 代谢科技有限公司 | Stability of vitamin D in beta-hydroxy-beta-methylbutyric acid (HMB) |
| CN110801018A (en) * | 2019-11-08 | 2020-02-18 | 广东医科大学 | Coenzyme Q10Vitamin C sports buccal tablet |
| CN111228468A (en) * | 2020-01-14 | 2020-06-05 | 浙江赛沛力运动科技有限公司 | Liquid preparation with effects of improving exercise endurance and helping exercise recovery |
| CN116076740A (en) * | 2023-03-13 | 2023-05-09 | 湖南她练生物科技有限公司 | Levocarnitine composition for improving metabolic fat function of sports females and preparation method thereof |
| CN116076740B (en) * | 2023-03-13 | 2024-07-16 | 湖南她练生物科技有限公司 | Stirring device for preparing L-carnitine preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102512655B (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102512655B (en) | L-carnitine composition, L-carnitine preparation and preparation method and application thereof | |
| CN103783532B (en) | A kind of composite protein powder of anti-sarcopenia decay and preparation method thereof | |
| CN108651998A (en) | It is a kind of have relieve fatigue PURE WHEY of function and preparation method thereof | |
| CN1364430A (en) | Method for storaging acid liquid or semiliquid composition containing kreatin for human consumption | |
| CN108618129A (en) | Sarcopenia tailored version clinical nutrition formula and preparation method thereof | |
| TWI721248B (en) | Anti-fatigue composition used for increasing endurance performance | |
| CN106889412A (en) | One kind is refreshed oneself anti-fatigue solid beverage | |
| CN101036515A (en) | Physical recovery healthy food and preparation process thereof | |
| CN101569412B (en) | Sports nutrition supplement and application thereof | |
| CN108606269B (en) | Sports nutritional supplement and preparation method thereof | |
| CN109757733A (en) | A kind of oral polypeptide powder and its preparation method and application | |
| CN112674351A (en) | Composition for improving cognitive function speed | |
| CN103704711B (en) | Granules with anti-fatigue and health-care function | |
| US20230125271A1 (en) | Muscle enhancer | |
| CN105919094A (en) | Immunity improving and fatigue preventing composition and preparation method thereof | |
| CN101214052B (en) | Health food with physical energy fatigue alleviating and immunity reinforcing function | |
| CN106509540A (en) | Drink for enhancing immunity and improving athletic ability | |
| CN103110114B (en) | Beta-alanine-containing composition for endurance increase, and preparation thereof | |
| JP2017057147A (en) | Composition comprising garlic and the like, low-salinity miso, and vitamin b1 | |
| RU2614881C1 (en) | Complex of biologically active substances, protecting athletes against over-training | |
| CN101574145B (en) | Nutritional reinforced supplement | |
| CN113854566A (en) | Nutritional supplement | |
| RU2390271C1 (en) | Preparation for increasing of organism adaptability to extreme conditions | |
| CN1315418C (en) | Instant drinking powder contg. black-fungus, oatmeal and spirulina, and its prepn. method | |
| CN103005435A (en) | Anti-fatigue composition capable of improving speed endurance and preparation containing anti-fatigue composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wei Bing Inventor after: Li Qigeng Inventor after: Bai Houzeng Inventor after: Jiao Ying Inventor after: Yang Zeyi Inventor after: Zhu Lianjun Inventor after: Liu Yuhua Inventor before: Bai Houzeng Inventor before: Jiao Ying Inventor before: Yang Zeyi Inventor before: Zhu Lianjun Inventor before: Liu Yuhua |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230609 Address after: 102200 No. 5, Lixiang Road, Science Park, Changping District, Beijing Patentee after: BEIJING COMPETITOR SPORTS SCIENCE & TECHNOLOGY Co.,Ltd. Patentee after: Gu'an kangbit Sports Technology Co.,Ltd. Address before: No. 5, Lixiang Road, Science Park, Changping District, Beijing 100069 Patentee before: BEIJING COMPETITOR SPORTS SCIENCE & TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |